Home / Health / Russia Develops AI Cancer Vaccine
Russia Develops AI Cancer Vaccine
11 Dec
Summary
- Russia produced first AI-assisted mRNA cancer vaccine batches.
- Preclinical studies showed tumor shrinkage of 60-80%.
- The personalized vaccine uses patient's genetic data for treatment.
Russian scientists have successfully produced the initial three experimental batches of a novel AI-assisted mRNA cancer vaccine at Moscow's Gamaleya Institute. This breakthrough therapy is designed to leverage a patient's unique genetic information to train their immune system to target and destroy malignant tumors. Preliminary preclinical studies indicated promising results, showing tumor shrinkage rates of 60-80%.
The personalized nature of this vaccine, developed with artificial intelligence, allows for a tailored approach to cancer treatment. Unlike conventional vaccines that prevent illness, these mRNA-based therapies are designed for individuals with advanced-stage cancer, effectively training the immune system to recognize and eliminate cancerous cells.
The Gamaleya Institute, internationally recognized for its development of the Sputnik V COVID-19 vaccine, has received full regulatory approval for the technology from diagnostics to patient administration. While these batches are experimental, they have passed all quality checks, signaling a significant step forward in personalized oncology.
